The Efficacy of Siltartoxatug in Preventing Post-Traumatic Tetanus Antibody Titers in the Elderly Population: A Multicenter Prospective Observational Study

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2500114172

Enrollment

Unknown

Registered

2025-12-08

Start date

2025-12-10

Completion date

Unknown

Last updated

2025-12-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

tetanus

Interventions

Elderly group with impaired liver and kidney function:None

The ordinary elderly group:None

Elderly group with liver dysfunction:None

Elderly group with renal insufficiency:None

Eligibility

Sex/Gender

All

Age

65 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Patients aged >= 65 years presenting with traumatic injuries at multiple clinical centers between December 2025 and September 2026 were prospectively and consecutively enrolled. 2.Patient received Siltartoxatug for tetanus prophylaxis following clinical assessment. 3. Subjects were included following the provision of written informed consent.

Exclusion criteria

Exclusion criteria: 1. Inability or refusal to provide informed consent. 2. Anticipated inability to complete at least 90 days of follow-up. 3. Presence of immunodeficiency. 4. Participation in other interventional clinical trials related to oncology within 30 days prior to enrollment.

Design outcomes

Primary

Measure	Time frame
Tetanus antibody titer;	—

Secondary

Measure	Time frame
Adverse Effects Rate;	—

Countries

China

Contacts

Public ContactTao Yu

Sun Yat-sen Memorial Hospital, Sun Yat-sen University

dryutao@yeah.net+86 135 0304 0061

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026